Press Release:

Major Inconsistencies in Recent IPO Scandal Revealed

Deep Knowledge Analytics Independent Investigation Into Recent Claims of Misconduct Against NASDAQ-Listed Company Uncovers False Claims & Research Flaws for Accusers

The analysis includes 4 different pieces, named “Nanox Company Composite Analysis”, “Informational Note (Summary): Analysis of 'Unusual Trading Activity' Surrounding Nanox in 2020”, “Informational Summary about Short Sellers: Citron Research and Muddy Waters”, and full report “Unusual Trading Activity’ at Nasdaq related to the shares of Nanox”.

 Head of Computational Molecular Design of Bayer AG, quoted Deep Pharma Intelligence on LinkedIn 

"...really cool to see Bayer on top of the list (Deep Pharma Intelligence, of pharma companies, embracing the #digitalization through collaborations with #ai companies. Leading or being involved in some of those collaborations, I can honestly say that this fundamentally changes the way how we work."

Thinktank calls for better co-ordination of mobile health applications

The thinktank, which provides the secretariat for the UK All-Party Parliamentary Group on Artificial Intelligence, has published the Global mHealth Industry Landscape Overview 2020 in collaboration with Deep Knowledge Analytics, looking at 260 companies active in the field and broken down on a regional basis.

Deep Knowledge Participated in Sibiu Innovation Days

The project manager of the Deep Knowledge Analytics, Anastasia Lit has conducted the presentation "Artificial Intelligence Industry in the Europe 2020" last week at Sibiu Innovation Days.

On the panel 1 "Artificial Intelligence", Anastasia presented the overview of AI in the EU Landscape with influencers list and regional distribution.

The recording is accessible.

The lucrative business

of living longer

Our report "Longevity Industry in UK. Landscape Overview 2018" was mentioned by Financial Times in a huge article about Longevity

Pharma’s AlphaGo Moment: For the First Time, Artificial Intelligence Has Designed a New Drug in 21 Days

Insilico Medicine succeeds in using AI to design a new molecule from scratch in just 21 days, and validate it in just 25 days, compared to 2-3 years required currently for pharma industry.

This is Pharma’s AlphaGo moment.
In 2015 DeepMind succeeded in developing the first AI capable of beating a human Go champion in Go. This may be an analogous game-changing moment for Pharma. The potential for AI to radically transform Pharma is obvious.

Pharma companies put faith

in AI for breakthroughs

Billions are being bet to find the next revolutionary drug. In 2013, US start-up Berg was asked by the Department of Defense to help improve the detection of prostate cancer, a disease common among pilots. Less than five years later, an artificial intelligence-driven tool has been tested on more than 1,000 patients with promising results.

UK in strong position to be leader in crypto economy, report says

UK in strong position to be leader in crypto economy, report says Britain has required resources to be global hub for blockchain technology, analysts say

Isn't It Time Banks And Crypto-Exchanges Made Friends?

"Why is the UK, the global financial heavyweight, with a liberal market economy, smart regulatory environment and excitement for innovation, not a leader now?"

PharmTech quoted AI-Friendly CEOs and Board Members report

Deep Knowledge Analytics also released a report examining AI, which examined practices at 50 pharmaceutical companies to identify leaders who are most actively driving the use of AI in their organizations.

Importance of senior management

The goal of this research is to benchmark the impact of management support on the use of AI and overall efforts to increase R & D efficiency, according to Margaretta Colangelo, managing partner at Deep Knowledge Ventures. She expects future research to find a correlation between level of commitment to AI and market capitalization growth.

Elsevier quoted DKA article on the Pharma R&D Today blog

“China’s ability to generate massive amounts of real-time medical data from more than 1 billion people in the local population, stimulated by rather flexible privacy laws is driving advancement,” writes Margaretta Colangelo of Deep Knowledge Ventures. Though she says that government programs are also helping to grow local AI and data science talent, Colangelo also warns that China is currently lagging behind its competitors in pharma and biotech innovation, which could limit its progress.